KRAS mutations in Slovene patients with colorectal cancer: Frequency, distribution and correlation with the response to treatment

International Journal of Oncology

Volumn 36, Issue 5, 2010, Pages 1137-1144

  Licar, Alenka ^a   Cerkovnik, Petra ^a   Ocvirk, Janja ^a   Novakovic, Srdjan ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Colorectal cancer; KRAS; Metastatic; Mutation

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; COLORECTAL CANCER; DIAGNOSTIC KIT; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; MALE; METASTASIS; ONCOGENE K RAS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ALLELES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SLOVENIA;

EID: 77950398199     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000596     Document Type: Article

References (33)

1. Harari PM, Allen GW and Bonner JA: Biology of interactions: anti-epidermal growth factor receptor agents. J Clin Oncol 25: 4057-4065, 2007.
2. Hemming AW, Davis NL, Kluftinger A, Robinson B, Quenville NF, Liseman B and Lcriche J: Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 51: 147-152, 1992.
3. Kluftinger AM, Robinson BW, Quenville NF, Finley RJ and Davies NJ: Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1: 97-105, 1992.
4. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K and Ludwig H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71: 2454-2460, 1993.
5. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
6. Spano JP, Lagorce C, Atlan D, et al: Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16: 102-108, 2005.
7. Bonomi PD, Buckingham L and Coon J: Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 13: s4606-s4612, 2007.
8. Rivera F, Vega-Villegas ME, Lopez-Brea MF and Marquez R: Current situation of panitumumab, matuzumab, nimotuzumab and zalutuzumab. Acta Oncol 47: 9-19, 2008.
9. Dassonville O, Bozec A, Fischel JL and Milano G: EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 62: 53-61, 2007.
10. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Cancer J Clin Oncol 26: 1626-1634, 2008.
11. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T and Nishio K: Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 98: 1275-1280, 2007.
12. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
13. Lievre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
14. De Roock W, Piessevaux H, De Schutter J, et al: KRAS mutation status and early radiological response predict survival in colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515, 2008.
15. Vetter IR and Wittinghofer A: The guanine nucleotide-binding switch in three dimensions. Science 294: 1299-1304, 2001.
16. Wennerberg K, Rossman KL and Der CJ: The Ras superfamily at a glance. J Cell Sci 118: 843-846, 2005.
17. Van Krieken JHJM, Jung A, Kirchner T, et al: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for a European quality assurance program. Virchows Arch 453: 417-431, 2008.
18. Kiaris H and Spandidos DA: Mutations of ras genes in human tumors (Review). Int J Oncol 7: 413-421, 1995.
19. Glarakis IS, Savva S and Spandidos DA: Activation of the ras genes in malignant and premalignant colorectal tumors. Oncol Rep 5: 1451-1454, 1998.
20. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85: 692-696, 2001.
21. Keller JW, Franklin JL, Graves-Deal R, Friedman DB, Whitwell CV and Coffey RJ: Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. J Cell Physiol 210: 740-749, 2007.
22. Wang JY, Wang YH, Jao SW, et al: Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. Oncol Rep 16: 1245-1252, 2006.
23. Zenker M, Lehmann K, Schulz AL, et al: Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 44: 131-135, 2007.
24. Cross J: Company Profile: DxS Ltd. Pharmacogenomics 9: 463-467, 2008.
25. DxS Limited: TheraScreen KRAS mutation Kit: Instructions for use. 2009.
26. Bos JL, Fearon ER, Hamilton ER, Verlaan-de Vries M, van Boom JH, van der Eb AJ and Vogelstein B: Prevalence of ras mutations in human colorectal cancers. Nature 327: 293-297, 1987.
27. Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10: 789-799, 2004.
28. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169, 2007.
29. Gnanasampanthan G, Elsaleh H, McCaul K and Iacopetta B: Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer. J Pathol 195: 543-548, 2001.
30. Neumann J, Zeindl-Eberhart E, Kirchner T and Jung A: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205: 858-862, 2009.
31. Santini D, Loupakis F and Vincenzi B: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practise. Oncologist 13: 1270-1275, 2008.
32. Artale S, Sartore-Bianchi A and Veronese SM: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26: 4217-4219, 2008.
33. Linardou H, Dahabreh IJ, Kanaloupiti D, et al: Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small lung cancer and metastatic colorectal cancer. Lancet Oncol 9: 962-972, 2008.